ORPHA:34145
Immunoglobulin A nephropathy
Also known as: Berger disease · IgA nephropathy
Publications
27,037
Trials
207
Interventional, condition-specific
Researchers
1,058
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare glomerular disease, histologically characterized by glomerular mesangial deposits of IgA, often accompanied by IgG and complement C3 as well as mesangioproliferative changes, clinically mostly manifesting as oligosymptomatic glomerulonephritis, possibly infection-triggered macrohematuria and a variable course ranging from spontaneous remission to slow or rarely rapid progression to kidney failure.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0005342
- MeSH:D005922
- UMLS:C0017661
- NCIT:C34643
Additional Mondo synonyms (3)
Berger's disease · IgA Nephropathy · IgA glomerulonephritis
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
27,037 matched papers (16,351 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
207 matched on ClinicalTrials.gov (72 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
27,037
27,037 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
27,037 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
16,351 in the last 10 years · low confidence
Phrase hits: 27,037 · MeSH hits: 0
Who's working on it?
1,058
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Zhang Y12 papers · 2026
Department of Nephrology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, People's Republic of China.
Papers in Europe PMC - 02Li Y9 papers · 2026
Department of Health Management Center, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Papers in Europe PMC - 03Xu G8 papers · 2026
Department of Nephrology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 1, Minde Road, Donghu District, Nanchang, 330006, P. R. China. gaosixu@163.com.
Papers in Europe PMC - 04Yang Y8 papers · 2026
Department of Nephrology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 1, Minde Road, Donghu District, Nanchang, 330006, P. R. China.
Papers in Europe PMC - 05Suzuki Y7 papers · 2026
Department of Nephrology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Papers in Europe PMC - 06Wang Y7 papers · 2026
Department of Nephrology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Papers in Europe PMC - 07Chen J6 papers · 2026
Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Papers in Europe PMC - 08Chen X6 papers · 2026
Department of Nephrology, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, Fujian, China.
Papers in Europe PMC - 09Li X6 papers · 2026
School of Public Health, Zhengzhou University, Zhengzhou, 450001, People's Republic of China.
Papers in Europe PMC - 10Wang X6 papers · 2026
Department of Nephrology, Luwan Branch of Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, ,
Papers in Europe PMC
Clinical research
Is a treatment being tested?
207
interventional trials for this specific condition
207 interventional trials matched this specific condition name; 72 currently recruiting in our sample.
Data as of 27 July 2026
207 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 99.3th percentile).
low confidence · 99.3th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
207 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06654596·RECRUITING·Efficacy and Safety of Telitacicept in IgAN
Conditions: IgA Nephropathy (IgAN) · Kidney Diseases · Telitacicept · Glucocorticoid·Matched via name phrase
- NCT06712407·RECRUITING·Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
Conditions: IgA Nephropathy·Matched via name phrase
- NCT06774664·NOT YET RECRUITING·A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases
Conditions: IgA Nephropathy·Matched via name phrase
- NCT07541287·RECRUITING·A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
Conditions: IgA Nephropathy·Matched via name phrase
- NCT05248659·ENROLLING BY INVITATION·Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
Conditions: Immunoglobulin A Nephropathy·Matched via name phrase
- NCT07182227·RECRUITING·PS-002 for the Treatment of IgA Nephropathy in Adults
Conditions: Immunoglobulin A (IgA) Nephropathy·Matched via name phrase
- NCT06994845·RECRUITING·Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
Conditions: Primary Immunoglobulin A Nephropathy (IgAN)·Matched via name phrase
- NCT07052981·NOT YET RECRUITING·Clinical Study on the Efficacy and Safety of Telitacicept in the Treatment of Pediatric IgA Nephropathy or IgA Vasculitis Nephritis
Conditions: IgA Nephropathy (IgAN) · IgAVN·Matched via name phrase
- NCT06786338·NOT YET RECRUITING·A Study of SGB-9768 in Patients with Complement-mediated Kidney Diseases
Conditions: IgA Nephropathy (IgAN) · C3 Glomerulopathy · IC-MPGN·Matched via name phrase
- NCT06792799·RECRUITING·Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease
Conditions: Autoimmune Diseases · Systemic Lupus Erthematosus · Multi-Drug Resistant Nephrotic Syndrome · IgAN - IgA Nephropathy·Matched via name phrase
- NCT07074951·RECRUITING·Tonsillectomy and Immunosuppression in Caucasian Patients With High-risk IgA-nephropathy
Conditions: Primary IgA-nephropathy · High-risk · Caucasians·Matched via name phrase
- NCT05775042·RECRUITING·Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy
Conditions: IgA Nephropathy·Matched via name phrase
- NCT06819826·RECRUITING·A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria
Conditions: IgA Nephropathy (IgAN)·Matched via name phrase
- NCT07604311·NOT YET RECRUITING·Efficacy and Safety of Nefecon on Prevention of Relapse of IgA Nephropathy: a Randomized, Double-blinded, Placebo-Controlled Trial
Conditions: IgA Nephropathy (IgAN)·Matched via name phrase
- NCT06690359·NOT YET RECRUITING·IM19 CAR-T Cell Therapy for IgA Nephropathy Patients and Membranous Nephropathy Patients
Conditions: IgA Nephropathy · Membranous Nephropathy·Matched via name phrase
Observational and natural-history studies
35 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT03929887·RECRUITING·KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis
Conditions: Glomerular Disease · Minimal Change Disease · IgA Nephropathy · Membranous Nephropathy·Matched via name phrase
- NCT05190848·RECRUITING·Correlation of Microbiome and Metabonomics With IgA Nephropathy
Conditions: IgA Nephropathy·Matched via name phrase
- NCT03001947·RECRUITING·IgA Nephropathy Registration Initiative of High Quality (INSIGHT)
Conditions: IgA Nephropathy·Matched via name phrase
- NCT06676007·RECRUITING·A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy
Conditions: IgA Nephropathy (IgAN) · Early Initial Therapy·Matched via name phrase
- NCT06065852·RECRUITING·National Registry of Rare Kidney Diseases
Conditions: Adenine Phosphoribosyltransferase Deficiency · AH Amyloidosis · AHL Amyloidosis · AL Amyloidosis·Matched via name phrase
- NCT06760845·RECRUITING·Raman Spectroscopy Diagnosis of Kidney Diseases
Conditions: IgA Nephropathy (IgAN) · Membranous Nephropathy · Diabetic Nephropathy · Focal Segmental Glomerulosclerosis (FSGS)·Matched via name phrase
- NCT07649538·NOT YET RECRUITING·Mediators of Loin Pain in IgA Nephropathy
Conditions: IgA Nephropathy (IgAN)·Matched via name phrase
- NCT06926244·RECRUITING·RESistance of IgA Nephropathy to Conventional and Newly-approved Therapies: an Observational, Real-life Study (RESIGAN)
Conditions: IgA Nephropathy (IgAN)·Matched via name phrase
- NCT07481084·NOT YET RECRUITING·IgA Nephropathy Insights From Treatment Experience Among Patients Receiving Iptacopan and/or Atrasentan Using Primary Data Collection
Conditions: IgA Nephropathy·Matched via name phrase
- NCT06952426·RECRUITING·A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US
Conditions: Immunoglobulin A Nephropathy·Matched via name phrase
- NCT05234463·RECRUITING·Study of the Link Between Complement Activation and IgA Nephropathy Severity
Conditions: IgA Nephropathy Severity in Kidney Transplantation·Matched via name phrase
- NCT02954419·RECRUITING·IgA Nephropathy Biomarkers Evaluation Study (INTEREST)
Conditions: IgA Nephropathy · Glomerular Diseases·Matched via name phrase
- NCT07010250·RECRUITING·Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis
Conditions: ANCA Associated Vasculitis · Extramembranous Glomerulopathy · Nephrotic Syndrome, Minimal Change · Interstitial Nephritis·Matched via name phrase
- NCT07585981·RECRUITING·Early Application of Budesonide Enteric-coated Capsules in the Treatment of Primary IgA Nephropathy.
Conditions: IgA Glomerulonephritis·Matched via name phrase
- NCT07555301·NOT YET RECRUITING·Clinical Experience With Sparsentan in Switzerland in IgA Nephropathy
Conditions: IgA Nephropathy (IgAN)·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Immunoglobulin A nephropathy" OR "Berger disease" OR "IgA nephropathy" OR "Berger's disease" OR "IgA glomerulonephritis"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Immunoglobulin A nephropathy" OR "Berger disease" OR "IgA nephropathy" OR "Berger's disease" OR "IgA glomerulonephritis"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 207 interventional · 35 observational · 1 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (27037) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-26T23:39:06.749Z
